相似文献
1
Aducanumab: Appropriate use recommendations.
Alzheimers Dement. 2022 Mar;18(3):531-533. doi: 10.1002/alz.12444. Epub 2021 Jul 27.
2
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
JAMA Neurol. 2022 Jan 1;79(1):13-21. doi: 10.1001/jamaneurol.2021.4161.
3
Aducanumab: Appropriate Use Recommendations.
J Prev Alzheimers Dis. 2021;8(4):398-410. doi: 10.14283/jpad.2021.41.
4
Aducanumab: Appropriate Use Recommendations Update.
J Prev Alzheimers Dis. 2022;9(2):221-230. doi: 10.14283/jpad.2022.34.
5
Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
Alzheimers Dement. 2024 May;20(5):3406-3415. doi: 10.1002/alz.13755. Epub 2024 Apr 3.
6
Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
J Alzheimers Dis. 2021;84(4):1457-1460. doi: 10.3233/JAD-215275.
7
Aducanumab for Alzheimer's disease: A regulatory perspective.
Pharmacol Res. 2021 Sep;171:105754. doi: 10.1016/j.phrs.2021.105754. Epub 2021 Jul 2.
8
What to Know About the Alzheimer Drug Aducanumab (Aduhelm).
JAMA Intern Med. 2022 Aug 1;182(8):892. doi: 10.1001/jamainternmed.2022.1039.
9
A Time-to-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease.
J Clin Pharmacol. 2022 Aug;62(8):1030-1046. doi: 10.1002/jcph.2047. Epub 2022 Apr 4.
10
Aducanumab: First Approval.
Drugs. 2021 Aug;81(12):1437-1443. doi: 10.1007/s40265-021-01569-z.
引用本文的文献
1
γ-secretase targeting in Alzheimer's disease.
J Alzheimers Dis Rep. 2025 Jun 23;9:25424823251349529. doi: 10.1177/25424823251349529. eCollection 2025 Jan-Dec.
2
Use of anti-amyloid therapies for Alzheimer's disease in Brazil: a position paper from the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology.
Dement Neuropsychol. 2024 Nov 11;18:e2024C002. doi: 10.1590/1980-5764-DN-2024-C002. eCollection 2024.
3
Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies.
Signal Transduct Target Ther. 2024 Aug 23;9(1):211. doi: 10.1038/s41392-024-01911-3.
4
Value of Knowing: Health-Related Behavior Changes following Amyloid PET Results Disclosure in Mild Cognitive Impairment.
J Prev Alzheimers Dis. 2024;11(4):958-965. doi: 10.14283/jpad.2024.50.
5
Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease.
J Neurol Neurosurg Psychiatry. 2024 Aug 16;95(9):796-803. doi: 10.1136/jnnp-2024-333468.
6
Associations Between Neuroinflammation-Related Conditions and Alzheimer's Disease: A Study of US Insurance Claims Data.
J Alzheimers Dis. 2024;99(2):739-752. doi: 10.3233/JAD-231286.
7
Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer's disease.
Cell Rep Med. 2024 Feb 20;5(2):101379. doi: 10.1016/j.xcrm.2023.101379.
8
Alzheimer's Disease: Treatment Today and Tomorrow.
Ann Indian Acad Neurol. 2023 Jul-Aug;26(4):326-333. doi: 10.4103/aian.aian_254_23. Epub 2023 Aug 28.
9
Alzheimer's Disease: A Review of Pathology, Current Treatments, and the Potential Therapeutic Effect of Decreasing Oxidative Stress by Combined Vitamin D and l-Cysteine Supplementation.
Antioxid Redox Signal. 2024 Apr;40(10-12):663-678. doi: 10.1089/ars.2023.0245. Epub 2023 Dec 8.
10
Precision medicine in neurodegeneration: the IHI-PROMINENT project.
Front Neurol. 2023 Aug 2;14:1175922. doi: 10.3389/fneur.2023.1175922. eCollection 2023.
本文引用的文献
1
Aducanumab: Appropriate Use Recommendations.
J Prev Alzheimers Dis. 2021;8(4):398-410. doi: 10.14283/jpad.2021.41.
2
Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.
Alzheimers Dement. 2019 Feb;15(2):292-312. doi: 10.1016/j.jalz.2018.09.009. Epub 2018 Dec 13.
Zotero 插件